Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers, as well as in preclinical stage to treat prostate, ovarian, brain, and pancreatic cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to detect cancer. The company has a collaborative research program with Patrys Limited and The University of Sydney. Imagion Biosystems Limited was incorporated in 2016 and is based in South Melbourne, Australia.
| 0.035 | |
| 0.035 | |
| - | |
| 0.035 | |
| 0.035 | |
| 0.035-1.436 | |
| 1 288 K | |
| 32 647 K | |
| 4 971 K | |
| -0.0005 | |
| 2.176 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Imagion Biosystems Limited (ASX:IBX) shareholders have seen the share price descend 13% over the month. But in three years the returns have been great. In three years the stock price has launched 113%...
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after lis...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
